摘要
目的探讨功能性消化不良(FD)患者采用雷贝拉唑与莫沙必利联合治疗的影响。方法选取2018年10月至2020年2月淮滨县人民医院收治的FD患者60例,按照随机摸球法分成观察组与对照组,每组30例。对照组使用莫沙必利治疗,观察组在对照组基础上使用雷贝拉唑治疗,比较两组临床疗效、症状评分、胃肠排空率、胃肠激素水平、不良反应,随访6个月,统计复发率。结果观察组治疗有效率与对照组相比明显更高,差异有统计学意义(P<0.05);两组治疗后腹痛、嗳气、胃部灼烧感评分明显降低,差异有统计学意义(P<0.05),观察组评分较对照组明显更低,差异有统计学意义(P<0.05);两组治疗后胃肠排空率均明显提高,差异有统计学意义(P<0.05),观察组明显高于对照组,差异有统计学意义(P<0.05);两组治疗后胃动素(MOT)、促胃泌素(GAS)水平明显提高,差异有统计学意义(P<0.05),生长抑素(SS)、血管活性肽(VIP)水平明显降低,差异有统计学意义(P<0.05)。观察组MOT、GAS水平明显高于对照组,差异有统计学意义(P<0.05),SS、VIP水平明显低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率(10.00%VS13.33%)比较,差异无统计学意义(P>0.05);随访6个月,观察组复发率明显低于对照组,差异有统计学意义(P<0.05)。结论FD患者采用雷贝拉唑与莫沙必利联合治疗能够起到明显疗效,可缓解临床症状、降低复发率,对改善胃肠动力及胃肠激素水平有着重要作用。
Objective To investigate the effects of rabeprazole combined with mosapride on functional dyspepsia(FD).Methods A total of 60 FD patients admitted to Huaibin County People's Hospital from October 2018 to February 2020 were randomly divided into observation group and control group,with 30 patients in each group.The control group was treated with mosapride,and the observation group was treated with rabeprazole on the basis of the control group.gastrointestinal hormone level and adverse reactions were compared between the two groups.The recurrence rate was counted after 6 months follow-up.Results The effective rate of observation group was significantly higher than that of control group,and the difference was statistically significant(P<0.05).After treatment,the scores of abdominal pain,belching and burning sensation in stomach were significantly decreased in the two groups,the differences were statistically significant(P<0.05).The scores of observation group were significantly lower than those of control group,the differences were statistically significant(P<0.05).After treatment,the gastrointestinal empty-rate in both groups was significantly increased,the difference was statistically significant(P<0.05),and the observation group was significantly higher than the control group,the difference was statistically significant(P<0.05).After treatment,motilin(MOT)and gastrin(GAS)levels in the two groups were significantly increased,the difference was statistically significant(P<0.05),while somatostatin(SS)and vasoactive peptide(VIP)levels were significantly decreased,the difference was statistically significant(P<0.05).MOT and GAS levels in the observation group were significantly higher than those in the control group.The SS and VIP levels were significantly lower than those of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(10.00%VS 13.33%)(P>0.05).After 6 months of follow-up,the recurrence rate of observation group was significantly lower than that of control group,the difference was statistically significant(P<0.05).Conclusion The treatment of FD patients with the combination of lebelazole and moxanilli can be significantly effective,which can relieve the clinical symptoms and reduce the recurrence rate,and have an important role in improving gastrointestinal power and gastrointestinal hormone levels.
作者
张克辉
ZHANG Kehui(Department of Gastroenterology,Huaibin County People's Hospital,Xinyang City,Henan Province,Huaibin Henan 464400,China)
出处
《临床研究》
2022年第7期112-115,共4页
Clinical Research
关键词
雷贝拉唑
莫沙必利
功能性消化不良
临床疗效
胃肠动力
rabeprazole
mosapride
functional dyspepsia
clinical efficacy
gastrointestinal motility
